                         SEQUENCE LISTING

<110>  Susavion Biosciences, Inc.
 
<120>  Method of Treatment of Neutrophil-Driven Inflammatory Pathologies

<130>  24667.047PCT2

<150>  63/057,741
<151>  2020-07-28

<160>  10    

<170>  PatentIn version 3.5

<210>  1
<211>  12
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence

<400>  1

Val Gln Ala Thr Gln Ser Asn Gln His Thr Pro Arg 
1               5                   10          


<210>  2
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence

<400>  2

Asn Pro Ser His Pro Leu Ser Gly 
1               5               


<210>  3
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence

<400>  3

Gly Gly Gly Ser 
1               


<210>  4
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence

<400>  4

Gly Gly Gly Ser Gly Gly Gly Ser 
1               5               


<210>  5
<211>  4
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence

<400>  5

Ser Ser Ser Ser 
1               


<210>  6
<211>  8
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence

<400>  6

Ser Ser Ser Ser Ser Ser Ser Ser 
1               5               


<210>  7
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  VQATQSNQHTPRGGGS linked to the N terminus

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  VQATQSNQHTPRGGGS linked to the end of the side chain lysyl

<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  AMIDATION

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  VQATQSNQHTPRGGGS linked to the N-terminus

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  VQATQSNQHTPRGGGS linked to the end of the side chain lysyl

<400>  7

Lys Lys Lys 
1           


<210>  8
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  NQHTPRGGGS linked to the N-terminus

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  NQHTPRGGGS linked to the end of the side chain lysyl

<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  AMIDATION

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  NQHTPRGGGS linked to the N-terminus

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  NQHTPRGGGS linked to the end of the side chain lysyl

<400>  8

Lys Lys Lys 
1           


<210>  9
<211>  3
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  NPSHPLSGGGGS linked to the N-terminus

<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  NPSHPLSGGGGS linked to the end of the side chain lysyl

<220>
<221>  MOD_RES
<222>  (2)..(2)
<223>  AMIDATION

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  NPSHPLSGGGGS linked to the N-terminus

<220>
<221>  MISC_FEATURE
<222>  (3)..(3)
<223>  NPSHPLSGGGGS linked to the end of the side chain lysyl

<400>  9

Lys Lys Lys 
1           


<210>  10
<211>  14
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic sequence


<220>
<221>  X
<222>  (1)..(8)
<223>  X is equal to any amino acid residue or is absent so long as the 
       sequence comprises at least 7 amino acid residues and at least 
       one amino acid residue preceding asparagine is a glutamine.

<400>  10

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Asn Gln His Thr Pro Arg 
1               5                   10                  


